259 related articles for article (PubMed ID: 30759236)
1. Targeting IDH1-Mutated Malignancies with NRF2 Blockade.
Liu Y; Lu Y; Celiku O; Li A; Wu Q; Zhou Y; Yang C
J Natl Cancer Inst; 2019 Oct; 111(10):1033-1041. PubMed ID: 30759236
[TBL] [Abstract][Full Text] [Related]
2. Blockade of Glutathione Metabolism in
Tang X; Fu X; Liu Y; Yu D; Cai SJ; Yang C
Mol Cancer Ther; 2020 Jan; 19(1):221-230. PubMed ID: 31548295
[TBL] [Abstract][Full Text] [Related]
3. Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism.
Yu D; Liu Y; Zhou Y; Ruiz-Rodado V; Larion M; Xu G; Yang C
Proc Natl Acad Sci U S A; 2020 May; 117(18):9964-9972. PubMed ID: 32312817
[TBL] [Abstract][Full Text] [Related]
4. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
[TBL] [Abstract][Full Text] [Related]
5. Reductive carboxylation supports redox homeostasis during anchorage-independent growth.
Jiang L; Shestov AA; Swain P; Yang C; Parker SJ; Wang QA; Terada LS; Adams ND; McCabe MT; Pietrak B; Schmidt S; Metallo CM; Dranka BP; Schwartz B; DeBerardinis RJ
Nature; 2016 Apr; 532(7598):255-8. PubMed ID: 27049945
[TBL] [Abstract][Full Text] [Related]
6. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A
Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670
[TBL] [Abstract][Full Text] [Related]
7. Brusatol Enhances the Radiosensitivity of A549 Cells by Promoting ROS Production and Enhancing DNA Damage.
Sun X; Wang Q; Wang Y; Du L; Xu C; Liu Q
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347930
[TBL] [Abstract][Full Text] [Related]
8. Energy Metabolism in
van Noorden CJF; Hira VVV; van Dijck AJ; Novak M; Breznik B; Molenaar RJ
Cells; 2021 Mar; 10(3):. PubMed ID: 33810170
[TBL] [Abstract][Full Text] [Related]
9. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
Warfel NA; Sainz AG; Song JH; Kraft AS
Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
[TBL] [Abstract][Full Text] [Related]
10. RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.
Zarei M; Lal S; Vaziri-Gohar A; O'Hayer K; Gunda V; Singh PK; Brody JR; Winter JM
Mol Cancer Res; 2019 Feb; 17(2):508-520. PubMed ID: 30266754
[TBL] [Abstract][Full Text] [Related]
11. Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation.
Liu HY; Tuckett AZ; Fennell M; Garippa R; Zakrzewski JL
Invest New Drugs; 2018 Aug; 36(4):590-600. PubMed ID: 29297149
[TBL] [Abstract][Full Text] [Related]
12. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
13. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.
Bai M; Yang L; Liao H; Liang X; Xie B; Xiong J; Tao X; Chen X; Cheng Y; Chen X; Feng Y; Zhang Z; Zheng W
Oncogene; 2018 Oct; 37(42):5666-5681. PubMed ID: 29921847
[TBL] [Abstract][Full Text] [Related]
14. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2.
Olayanju A; Copple IM; Bryan HK; Edge GT; Sison RL; Wong MW; Lai ZQ; Lin ZX; Dunn K; Sanderson CM; Alghanem AF; Cross MJ; Ellis EC; Ingelman-Sundberg M; Malik HZ; Kitteringham NR; Goldring CE; Park BK
Free Radic Biol Med; 2015 Jan; 78():202-12. PubMed ID: 25445704
[TBL] [Abstract][Full Text] [Related]
15. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
Gao Y; de Wit M; Struys EA; van der Linde HCZ; Salomons GS; Lamfers MLM; Willemsen R; Sillevis Smitt PAE; French PJ
PLoS One; 2018; 13(6):e0199737. PubMed ID: 29953513
[TBL] [Abstract][Full Text] [Related]
16. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ
Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?
Wu T; Harder BG; Wong PK; Lang JE; Zhang DD
Mol Carcinog; 2015 Nov; 54(11):1494-502. PubMed ID: 25154499
[TBL] [Abstract][Full Text] [Related]
18. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Calvert AE; Chalastanis A; Wu Y; Hurley LA; Kouri FM; Bi Y; Kachman M; May JL; Bartom E; Hua Y; Mishra RK; Schiltz GE; Dubrovskyi O; Mazar AP; Peter ME; Zheng H; James CD; Burant CF; Chandel NS; Davuluri RV; Horbinski C; Stegh AH
Cell Rep; 2017 May; 19(9):1858-1873. PubMed ID: 28564604
[TBL] [Abstract][Full Text] [Related]
19. The Roles of 4β-Hydroxywithanolide E from Physalis peruviana on the Nrf2-Anti-Oxidant System and the Cell Cycle in Breast Cancer Cells.
Peng CY; You BJ; Lee CL; Wu YC; Lin WH; Lu TL; Chang FC; Lee HZ
Am J Chin Med; 2016; 44(3):617-36. PubMed ID: 27109152
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of NRF2 in ROS-mediated tumor chemoresistance.
Xue D; Zhou X; Qiu J
Biomed Pharmacother; 2020 Nov; 131():110676. PubMed ID: 32858502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
